BRPI0511111A - compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários - Google Patents

compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários

Info

Publication number
BRPI0511111A
BRPI0511111A BRPI0511111-0A BRPI0511111A BRPI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A BR PI0511111 A BRPI0511111 A BR PI0511111A
Authority
BR
Brazil
Prior art keywords
protein kinase
synthesis
kinase inhibitors
compounds
intermediates
Prior art date
Application number
BRPI0511111-0A
Other languages
English (en)
Inventor
Gabriel Martinez-Botella
Michael R Hale
Francois Maltais
Qing Tang
Judth Straub
Original Assignee
Vertex Pharmaceuticals Incorpo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorpo filed Critical Vertex Pharmaceuticals Incorpo
Publication of BRPI0511111A publication Critical patent/BRPI0511111A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTOS DE PIRROL COMO INIBIDORES DE CINASE DE PROTEìNA DE ERK, SUA SìNTESE E SEUS INTERMEDIáRIOS. A presente invenção refere-se a compostos úteis de inibidores de proteína quinase. A invenção também provê composições farmaceuticamente aceitáveis compreendendo os ditos compostos e métodos de uso das composições no tratamento de vários distúrbios, condições ou distúrbios.
BRPI0511111-0A 2004-05-14 2005-05-13 compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários BRPI0511111A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14
PCT/US2005/016902 WO2005113541A1 (en) 2004-05-14 2005-05-13 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
BRPI0511111A true BRPI0511111A (pt) 2007-11-27

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511111-0A BRPI0511111A (pt) 2004-05-14 2005-05-13 compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários

Country Status (25)

Country Link
US (6) US7354939B2 (pt)
EP (5) EP3608315B1 (pt)
JP (1) JP5132305B2 (pt)
CN (1) CN1976919A (pt)
AR (2) AR051735A1 (pt)
AU (1) AU2005245885B2 (pt)
BR (1) BRPI0511111A (pt)
CA (1) CA2566461C (pt)
CY (1) CY1122336T1 (pt)
DK (1) DK3305776T3 (pt)
ES (4) ES2897422T3 (pt)
HU (1) HUE047130T2 (pt)
IL (1) IL179207A0 (pt)
LT (1) LT3305776T (pt)
MX (1) MXPA06013209A (pt)
NO (1) NO20065727L (pt)
NZ (1) NZ551582A (pt)
PL (1) PL3305776T3 (pt)
PT (1) PT3305776T (pt)
RU (1) RU2376299C2 (pt)
SI (1) SI3305776T1 (pt)
TW (1) TW200607803A (pt)
UA (1) UA84930C2 (pt)
WO (1) WO2005113541A1 (pt)
ZA (1) ZA200609975B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456190B2 (en) * 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
ES2897422T3 (es) * 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
AR068046A1 (es) * 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
CN102015693B (zh) 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
PT3058371T (pt) 2013-10-14 2021-07-26 Univ Indiana Res & Tech Corp Uso de acamprosato para modular a ativação de erk 1-2 em modelos animais de sxf e tea e indivíduos diagnosticados com sxf e tea
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
AU2014368912B2 (en) * 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 MEK and ERK inhibitors
EP3082957B1 (en) * 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
BR112016014481B1 (pt) 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
US11013743B2 (en) 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
AU2014368925A1 (en) * 2013-12-20 2016-07-21 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of MEK type I and ERK inhibitors
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
US9670177B2 (en) * 2015-01-30 2017-06-06 Biomed Valley Discoveries, Inc. Crystalline C21H22Cl2N4O2 malonate
SG11201705924RA (en) * 2015-01-30 2017-08-30 Biomed Valley Discoveries Inc CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
WO2016192064A1 (en) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
WO2016192063A1 (en) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR20190075931A (ko) 2016-10-05 2019-07-01 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 스피로 고리 화합물
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
EP3694518A1 (en) * 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US20230190725A1 (en) * 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
WO2023183905A2 (en) * 2022-03-24 2023-09-28 Biomed Valley Discoveries, Inc. Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE60003550T2 (de) * 1999-05-14 2004-04-15 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
ATE325114T1 (de) 1999-06-22 2006-06-15 Takeda Pharmaceutical Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7456190B2 (en) * 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
ES2897422T3 (es) * 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos

Also Published As

Publication number Publication date
CA2566461C (en) 2012-07-10
SI3305776T1 (sl) 2020-01-31
AR051735A1 (es) 2007-02-07
EP2799434A1 (en) 2014-11-05
HUE047130T2 (hu) 2020-04-28
PT3305776T (pt) 2019-12-17
AU2005245885A1 (en) 2005-12-01
US20230183276A1 (en) 2023-06-15
PL3305776T3 (pl) 2020-03-31
TW200607803A (en) 2006-03-01
ES2897422T3 (es) 2022-03-01
EP2799434B1 (en) 2017-08-02
JP2007537295A (ja) 2007-12-20
CY1122336T1 (el) 2021-01-27
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
US7354939B2 (en) 2008-04-08
RU2006144445A (ru) 2008-06-20
DK3305776T3 (da) 2019-12-09
US20060106069A1 (en) 2006-05-18
EP3305776A1 (en) 2018-04-11
JP5132305B2 (ja) 2013-01-30
EP1753738B1 (en) 2014-07-09
ES2751761T3 (es) 2020-04-01
EP3608315A1 (en) 2020-02-12
USRE48266E1 (en) 2020-10-20
USRE49500E1 (en) 2023-04-25
EP3943489A1 (en) 2022-01-26
AR106755A2 (es) 2018-02-14
EP3305776B1 (en) 2019-09-25
HK1203505A1 (en) 2015-10-30
ZA200609975B (en) 2008-02-27
AU2005245885B2 (en) 2011-01-20
CA2566461A1 (en) 2005-12-01
USRE46097E1 (en) 2016-08-09
EP1753738A1 (en) 2007-02-21
NZ551582A (en) 2011-01-28
CN1976919A (zh) 2007-06-06
HK1247910A1 (en) 2018-10-05
LT3305776T (lt) 2020-01-10
WO2005113541A1 (en) 2005-12-01
USRE47318E1 (en) 2019-03-26
NO20065727L (no) 2006-12-12
IL179207A0 (en) 2007-03-08
UA84930C2 (ru) 2008-12-10
ES2651439T3 (es) 2018-01-26
EP3608315B1 (en) 2021-08-11
ES2513965T3 (es) 2014-10-27

Similar Documents

Publication Publication Date Title
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
EP1597234A4 (en) NEW COMPOUNDS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.